LEN joins other WHO-encouraged PrEP options, which include daily oral PrEP, injectable cabotegravir as well as dapivirine vaginal ring, as Component of a developing arsenal of resources to end the HIV epidemic. Although access to LEN exterior medical trials remains restricted at this time, WHO urges governments, donors and world-wide https://maps.app.goo.gl/wHRWfY833JEXiqNx8